Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

2 Apr 2009 07:00

RNS Number : 9727P
ViaLogy PLC
02 April 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

VIALOGY TO RAISE UP TO £1.5 MILLION

LONDONApril 2, 2009 - ViaLogy PLC (LSE: VIY).  The Company today announces it is to offer investors who participated in ViaLogy's 2007 and 2008 funding rounds the opportunity to exercise their warrants at a reduced price.  It is proposed that the 27,500,000 warrants issued in October 2007 ("2009 Warrants") exercisable at 10 pence per Ordinary Share will be exercisable at 2.5 pence until noon on Thursday, 30 April 2009 (the "End Date") It is further proposed that the 45,000,000 warrants issued in October 2008 ("2010 Warrants") exercisable at 5 pence per Ordinary Share will be exercisable at 2 pence until the End Date In addition, for the 1,193,654 warrants held by George Rehm and Michael Kelly, both Directors, (exercisable at 4 pence per share) and a total of 2,500,000 warrants held by Dr Richard Dixey and Mark Tompkins (exercisable at 6 pence per share) will be reduced to 2 pence per share during the same period.

Full exercise of all outstanding 2009 Warrants and 2010 Warrants prior to the End Date, at the reduced subscription prices, would raise £1,587,500 (before expenses) for the Company. After the End Date, the original subscription prices relating to all such warrants will apply.

In accordance with the terms of their constitution, the proposed variation of the subscription prices applying to the 2009 Warrants and 2010 Warrants must be approved by, and is conditional upon the passing of, extraordinary resolutions to be proposed at meetings of the holders of such warrants. Accordingly, the Company has today convened meetings of the holders of the 2009 Warrants and the 2010 Warrants to be held on Monday, 20 April 2009.

The Company has also today entered into agreements with certain institutions and individuals ("Subscribers") who have undertaken to subscribe for such number of new Ordinary Shares ("Subscriber Shares") as has an aggregate subscription price of £1,587,500, less the aggregate amount of the proceeds of the exercise of warrants by warrant holders (the "Subscription").  The aggregate number of Ordinary Shares to be subscribed by such persons shall not, however, exceed 50,377,300 (representing approximately 10 per cent. of the Company's current issued share capital), which is the maximum number of Ordinary Shares the Directors are authorised to issue for cash, pursuant to resolutions passed at the Annual General Meeting of the Company held on 29 October 2008, other than pro rata to existing shareholders. The subscription price payable for the Subscriber Shares will be determined by the number of warrants which holders of the 2009 Warrants and 2010 Warrants elect to exercise, but shall be not less than 2 pence for the first 45 million Subscriber Shares and 2.5 pence for the remaining Subscriber Shares.

In consideration of the Subscribers agreeing to subscribe for the Subscriber Shares, and so guarantee that the amount of funds to be received by ViaLogy pursuant to the proposed fundraising, (before expenses) is not less than £1,034,432.50, the Company has agreed to pay to such Subscribers an aggregate fee of £79,375 being 5% of £1,587,500, which is the maximum amount to be raised by the Company, assuming full exercise of the 2009 Warrants and the 2010 Warrants. 

Application will be made for the Ordinary Shares issued upon the valid exercise of outstanding warrants and the Subscriber Shares to be admitted to trading on AIM.

"The board decided to re-price the warrants in conjunction with the Subscription for two main reasons," said ViaLogy chairman Terry Bond. "Firstly, shareholder dilution is minimised because the warrants are already accounted for in the Company's fully diluted financial position.  Secondly, ViaLogy needs additional funding for future on-going expenditure, including the opportunity to increase our financial participation in the successful well our QuantumRD technology has identified on the Galba Oil Prospect in south central Texas.  Atascosa Exploration LLC, who commissioned us to analyse the seismic data and advise on drilling locations, were so pleased with the results that they offered us very attractive terms to double ViaLogy's working interest in the first well production to 10%. The re-pricing of the warrants seemed a very elegant solution to our funding requirements whilst minimising any dilution effect."

Ends

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Nominated Advisor (Seymour Pierce)   Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 7628 5582 

About ViaLogy

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications.  ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential.  ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter.  This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications.  For more information, visit our website at www.ViaLogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEDGGDSBUGGGCB
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.